Nautilus Biotechnology, Inc.

Nautilus Biotechnology, Inc. (Nasdaq: NAUT) is a proteomics company that reached the public markets through a merger with Arya Sciences Acquisition Corp III, a blank-check vehicle sponsored by Arya Sciences Management LP and focused on the life sciences sector. The SPAC completed its initial public offering in 2020, targeting companies developing next-generation biological tools and therapeutics. Nautilus is building a single-molecule protein sequencing platform intended to support large-scale proteomics research and drug discovery applications. The de-SPAC transaction closed in 2021, after which the combined entity began trading under the NAUT ticker on Nasdaq. To access full filing history, investor data, and SPAC transaction analytics on Nautilus Biotechnology and thousands of other deals, sign up at SpacDesk.